At the news
? MIXEDIMPACT 6/10 8-K filed Mar 31, 2026 at 08:00 ET
Palvella Therapeutics reported Q4 2025 financial results with a net loss of $41.7 million ($3.71 per share), missing consensus by 15.4%. However, the company highlighted strong clinical progress, including positive Phase 3 data for QTORIN rapamycin in microcystic lymphatic malformations and a $230 million equity financing, leaving it with $274 million in pro forma cash. The stock may react negatively to the earnings miss but could be supported by the robust pipeline advancement and strengthened balance sheet.
- Net loss of $41.7 million for 2025, or $3.71 per share, missing consensus of $-0.93 by 15.4%.
- Raised $230 million in an oversubscribed public offering, resulting in $274 million of pro forma cash as of December 31, 2025.
- Reported positive Phase 3 SELVA study results for QTORIN rapamycin in microcystic lymphatic malformations, with NDA submission on track for 2H 2026.
- Initiation of Phase 3 trials for QTORIN rapamycin in cutaneous venous malformations and Phase 2 trials for two other indications are planned for 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access